NCT00193388
Completed
Phase 2
Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
ConditionsLung Cancer
DrugsTopotecan
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- SCRI Development Innovations, LLC
- Enrollment
- 100
- Primary Endpoint
- Overall response rate
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer
Detailed Description
Upon determination of eligibility, all patients will be receive: * Topotecan
Investigators
Eligibility Criteria
Inclusion Criteria
- •To be included in this study, you must meet the following criteria:
- •Small Cell Lung cancer
- •Progression after one previous regimen
- •Measurable or evaluable disease
- •Able to perform activities of daily living with assistance
- •Adequate bone marrow, liver and kidney function
- •No more than three previous courses of radiation therapy
- •Accessible for treatment and follow up
- •Must give written informed consent prior to study entry
Exclusion Criteria
- •You cannot participate in this study if any of the following apply to you:
- •Central nervous system involvement
- •Serious or active infection
- •Serious underlying medical condition
- •Other active neoplasms
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Outcomes
Primary Outcomes
Overall response rate
Secondary Outcomes
- Median survival
- 1-year survival
- Symptomatic improvement
Similar Trials
Completed
Phase 2
Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung CancerLung CancerNCT00193401SCRI Development Innovations, LLC40
Completed
Phase 2
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung CancerSmall Cell Lung CancerCarcinoma, Small CellNCT00294190SCRI Development Innovations, LLC38
Completed
Phase 2
Weekly Topotecan in Patients Treated for Metastatic Colorectal CancerColon CancerNCT00193167SCRI Development Innovations, LLC40
Completed
Phase 2
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung CancerExtensive Stage Small Cell Lung CancerRecurrent Small Cell Lung CancerNCT00828139National Cancer Institute (NCI)189
Completed
Phase 2
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) CancersOvarian NeoplasmsUterine NeoplasmsNCT00231855Montefiore Medical Center31